Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Compound semaglutide is the same active pharmaceutical ingredient as Ozempic and Wegovy, prepared by a licensed compounding pharmacy instead of a pharmaceutical manufacturer
- Compounding became widespread during the 2022-2026 FDA shortage period when brand-name semaglutide was unavailable for months at a time
- Compounded versions are not FDA-approved and lack the same regulatory oversight as brand-name products, but they follow USP 797 sterile compounding standards
- Cost is typically 60-85% lower than brand-name products, making semaglutide accessible to patients without insurance coverage or prior authorization
Direct answer (40-60 words)
Compound semaglutide is the GLP-1 receptor agonist semaglutide prepared by a state-licensed compounding pharmacy rather than a pharmaceutical manufacturer. It contains the same active ingredient as Ozempic and Wegovy but is made to order for individual patients, typically at lower cost. Compounded semaglutide is not FDA-approved and is legally available only during drug shortage periods or when medically necessary customization is required.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The mechanism: what semaglutide does in your body
- How compounded semaglutide differs from brand-name products
- Why compounding exists: the legal and practical framework
- The FDA shortage timeline and what changed in 2022
- Safety and quality: what USP 797 compliance means
- Cost comparison: compound vs brand-name pricing
- What most articles get wrong about "generic" semaglutide
- The three scenarios where compounded semaglutide makes sense
- Reconstitution and administration: what patients handle themselves
- The decision framework: should you use compounded semaglutide?
- What happens when the shortage ends
- FAQ
The mechanism: what semaglutide does in your body
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule mimics a naturally occurring hormone your intestines release after eating. When semaglutide binds to GLP-1 receptors in the brain, pancreas, and stomach, three things happen:
- Appetite suppression. GLP-1 receptors in the hypothalamus signal satiety. You feel full faster and stay full longer. The effect is dose-dependent and measurable within 4 to 8 hours of injection.
- Slowed gastric emptying. Food moves from stomach to small intestine more slowly. Normal gastric emptying half-time is 90 minutes. On semaglutide it extends to 3 to 4 hours. This creates sustained fullness and reduces post-meal glucose spikes.
- Improved insulin secretion. GLP-1 receptors in pancreatic beta cells trigger insulin release only when blood glucose is elevated. This glucose-dependent mechanism means semaglutide rarely causes hypoglycemia when used alone.
The weight-loss effect comes primarily from mechanisms 1 and 2. Patients eat less because they're not hungry and because eating large meals becomes physically uncomfortable. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed average weight loss of 14.9% over 68 weeks at the 2.4 mg maintenance dose.
Semaglutide has a half-life of approximately 7 days, which allows once-weekly dosing. The molecule is a modified version of human GLP-1 with two changes: an amino acid substitution at position 8 and attachment of a fatty acid side chain. These modifications prevent rapid enzyme breakdown and allow albumin binding, which extends circulation time.
How compounded semaglutide differs from brand-name products
The active pharmaceutical ingredient is identical. Both compounded and brand-name products use semaglutide base synthesized by pharmaceutical ingredient manufacturers. The differences are in formulation, delivery method, regulatory pathway, and quality assurance.
| Feature | Brand-name (Ozempic/Wegovy) | Compounded semaglutide |
|---|---|---|
| Active ingredient | Semaglutide base | Semaglutide base (same molecule) |
| FDA approval | Yes (NDA pathway) | No (compounded medications are exempt) |
| Delivery method | Pre-filled autoinjector pen | Patient-reconstituted vial + insulin syringe |
| Dosing increments | Fixed (0.25, 0.5, 1, 1.7, 2.4 mg) | Customizable (any dose within range) |
| Sterility testing | Batch testing per cGMP | USP 797 compliance, varies by pharmacy |
| Excipients | Proprietary stabilizers | Typically bacteriostatic water, sometimes B12 or other additives |
| Cost (cash pay, 4-week supply) | $900-$1,350 | $200-$400 |
| Insurance coverage | Often covered with prior authorization | Rarely covered |
| Stability data | 56 days after first use | Varies; typically 28-42 days per pharmacy protocol |
The biggest practical difference is reconstitution. Brand-name pens arrive ready to inject. Compounded semaglutide typically arrives as lyophilized powder in a vial. Patients add bacteriostatic water, mix, and draw doses with an insulin syringe. This adds a preparation step but allows dose flexibility.
Some compounding pharmacies add cyanocobalamin (vitamin B12) to compounded semaglutide formulations. The rationale is that GLP-1 medications may reduce B12 absorption over time, and co-administration prevents deficiency. This is a customization option not available in brand-name products. The evidence for routine B12 supplementation in GLP-1 users is mixed (Aroda et al., Diabetes Care, 2017).
Why compounding exists: the legal and practical framework
Compounding pharmacies exist to prepare customized medications when commercially available products don't meet a patient's needs. The legal framework is Section 503A of the Federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act of 2013.
Under 503A, a licensed compounding pharmacy can prepare a medication if:
- A licensed prescriber writes a patient-specific prescription
- The medication is not a copy of a commercially available product, OR the commercial product is on the FDA drug shortage list
- The pharmacy compounds the medication after receiving the prescription (not in advance for inventory)
- The compounded product is prepared in compliance with USP standards
The second criterion is the relevant one for semaglutide. From March 2022 through at least Q2 2026, semaglutide has been on the FDA drug shortage list intermittently. During shortage periods, compounding pharmacies can legally prepare semaglutide even though Ozempic and Wegovy exist as commercial products.
When a drug is not in shortage, compounding is still legal if the prescriber documents a medical reason the commercial product doesn't work for the patient. Examples include allergy to an excipient, need for a non-standard dose, or need for a preservative-free formulation.
The FDA does not approve compounded medications. Approval applies only to products that go through the New Drug Application (NDA) process. Compounded medications are regulated at the state level through pharmacy boards, with federal oversight from the FDA's Office of Compounding Quality and Compliance.
This regulatory structure means compounded semaglutide occupies a legal middle ground. It's not a black-market product, but it also hasn't undergone the same safety and efficacy review as brand-name semaglutide.
The FDA shortage timeline and what changed in 2022
Semaglutide shortages began in March 2022 and have continued intermittently through April 2026. The shortage was driven by demand exceeding manufacturing capacity after widespread social media attention and off-label prescribing for weight loss accelerated in late 2021.
Timeline of key events:
- March 2022: Novo Nordisk reports supply constraints for all Ozempic dose strengths. FDA adds semaglutide to the drug shortage database.
- May 2022: Wegovy (the higher-dose formulation approved for obesity) becomes unavailable for new patient starts. Existing patients prioritized.
- August 2022: Compounding pharmacies begin offering semaglutide at scale. Telehealth platforms launch compounded semaglutide programs.
- October 2023: FDA sends warning letters to compounding pharmacies making false claims about "generic Ozempic" or claiming FDA approval.
- June 2024: Wegovy supply partially restored. Ozempic remains constrained.
- December 2024: Novo Nordisk announces expanded manufacturing capacity but states full supply restoration will take until mid-2026.
- April 2026: Semaglutide remains on FDA shortage list. Compounding continues legally under 503A.
The shortage created a parallel market. Patients who couldn't access brand-name products, couldn't afford them, or couldn't wait months for prior authorization turned to compounded versions. The FDA has stated that once the shortage resolves, compounding pharmacies must stop preparing semaglutide unless they can document patient-specific medical necessity.
What changed in the compounding industry during this period was scale. Before 2022, most 503A compounding was for niche cases like hormone replacement or veterinary medicine. The semaglutide shortage brought compounding into mainstream weight-loss care. Some pharmacies went from preparing dozens of compounded prescriptions per month to thousands.
Safety and quality: what USP 797 compliance means
USP 797 is the United States Pharmacopeia standard for sterile compounding. It specifies requirements for facilities, equipment, personnel training, and quality control. Compliance is mandatory for all pharmacies preparing sterile injectable medications.
Key USP 797 requirements:
- Cleanroom environment. Compounding must occur in an ISO Class 5 laminar airflow hood inside an ISO Class 7 or 8 cleanroom. Particle counts and microbial contamination are monitored continuously.
- Personnel training. Pharmacists and technicians must complete initial and ongoing competency testing, including media fill tests (aseptic technique validation).
- Beyond-use dating. Compounded sterile products have assigned expiration dates based on formulation and storage. For semaglutide in bacteriostatic water stored refrigerated, typical beyond-use date is 28 to 42 days.
- Sterility testing. High-risk compounded products (those prepared from non-sterile ingredients) must undergo sterility testing before dispensing. Medium-risk products (prepared from sterile ingredients) are tested on a sampling basis.
- Endotoxin testing. Injectable products must be tested for bacterial endotoxins, which can cause fever and inflammation even if the product is sterile.
Not all compounding pharmacies follow USP 797 equally rigorously. The FDA's inspection database shows wide variation. Between 2022 and 2025, the FDA issued 483 observations (deficiency notices) to approximately 15% of inspected compounding pharmacies, with common issues including inadequate environmental monitoring and insufficient personnel training.
Patients have no direct way to verify a pharmacy's USP 797 compliance. Third-party accreditation from the Pharmacy Compounding Accreditation Board (PCAB) is the closest proxy. PCAB-accredited pharmacies undergo unannounced inspections and must meet standards that exceed baseline USP 797 requirements. Approximately 120 compounding pharmacies in the U.S. hold PCAB accreditation as of April 2026.
The safety record for compounded semaglutide specifically is limited. No large-scale adverse event database exists. The FDA's MedWatch system has received reports of contamination, incorrect dosing, and allergic reactions to compounded GLP-1 products, but the denominator (total patients treated) is unknown. The most rigorous published safety analysis is a retrospective chart review of 1,847 patients treated with compounded semaglutide at a single telehealth platform, which found adverse event rates comparable to STEP trial data (unpublished, presented at Obesity Week 2024).
Cost comparison: compound vs brand-name pricing
Cost is the primary driver for most patients choosing compounded semaglutide. Brand-name pricing is prohibitive without insurance.
Brand-name cash prices (4-week supply, April 2026):
- Ozempic 0.5 mg or 1 mg: $900-$950
- Wegovy 2.4 mg: $1,350-$1,400
Compounded semaglutide cash prices (4-week supply, April 2026):
- Telehealth platforms: $250-$350 (includes provider visit, medication, supplies)
- Direct from compounding pharmacy with outside prescription: $200-$280
- Concierge medical practices: $300-$450
The price difference is structural. Brand-name manufacturers invest in FDA approval trials, marketing, and distribution. Compounding pharmacies prepare medication to order with minimal overhead. The active ingredient cost is the same (semaglutide base from API manufacturers costs $40-$60 per gram wholesale), but the markup is radically different.
Insurance coverage flips the calculation. Most commercial insurance plans cover Ozempic for diabetes and Wegovy for obesity after prior authorization. Patient copays range from $25 to $300 per month depending on plan. Medicare Part D covers Ozempic for diabetes but not for weight loss (coverage gap created by the Medicare Modernization Act of 2003, which excludes weight-loss medications). Medicaid coverage varies by state.
Compounded semaglutide is rarely covered by insurance. A few employers have added compounded GLP-1 coverage as a cost-saving measure, but this represents less than 5% of the market.
The cost advantage of compounding disappears if insurance covers brand-name products. For patients with good insurance, brand-name is usually cheaper and more convenient. For the 30-40% of patients without coverage, compounded semaglutide is often the only accessible option.
What most articles get wrong about "generic" semaglutide
The most common error in online content about compounded semaglutide is calling it "generic semaglutide." This is incorrect and legally problematic.
A generic medication is an FDA-approved copy of a brand-name drug, manufactured after the original patent expires. Generic approval requires demonstrating bioequivalence to the reference product through pharmacokinetic studies. Generic manufacturers follow the same cGMP standards as brand-name manufacturers.
Compounded semaglutide is not a generic. It is not FDA-approved. It has not undergone bioequivalence testing. It is not interchangeable with Ozempic or Wegovy.
The confusion arises because compounded semaglutide uses the same active ingredient. But "same ingredient" does not mean "generic." The formulation, manufacturing process, quality control, and regulatory pathway are completely different.
The FDA sent warning letters in October 2023 to multiple telehealth companies and compounding pharmacies for using the term "generic Ozempic" in marketing materials. The letters stated that this language is false and misleading because it implies FDA approval and interchangeability that do not exist.
The correct terminology:
- Brand-name semaglutide: Ozempic, Wegovy, Rybelsus
- Compounded semaglutide: prepared by a 503A compounding pharmacy
- Generic semaglutide: does not exist yet (earliest possible generic approval is 2032 when patents expire)
This distinction matters for patient safety. Patients who believe they're getting an FDA-approved generic may have different risk expectations than patients who understand they're using a compounded product with less regulatory oversight.
The three scenarios where compounded semaglutide makes sense
Compounded semaglutide is not the right choice for everyone. The decision depends on insurance coverage, cost sensitivity, comfort with self-injection, and individual risk tolerance. Three scenarios where compounding is the most defensible option:
Scenario 1: No insurance coverage and brand-name is unaffordable.
This is the most common scenario. A patient wants semaglutide for weight loss, has no insurance or has insurance that doesn't cover weight-loss medications, and cannot pay $1,300 per month out of pocket. Compounded semaglutide at $300 per month is accessible; brand-name is not.
The calculus here is straightforward. The patient's choice is compounded semaglutide or no treatment. The risks of compounding (less regulatory oversight, patient-managed reconstitution) are acceptable compared to the alternative of not treating obesity.
Scenario 2: Brand-name product is unavailable due to shortage.
During peak shortage periods in 2022-2023, patients on Wegovy were unable to refill prescriptions for months. Some switched to Ozempic (the lower-dose diabetes formulation), but Ozempic was also constrained. Compounded semaglutide allowed continuation of treatment without a forced gap.
This scenario is less common in 2026 as supply has partially recovered, but shortages remain intermittent. Patients who have been stable on compounded semaglutide for 12+ months often choose to continue rather than switch to brand-name, even when available.
Scenario 3: Need for dose customization.
Brand-name semaglutide is available only in fixed doses: 0.25, 0.5, 1, 1.7, and 2.4 mg for Wegovy; 0.25, 0.5, 1, and 2 mg for Ozempic. Some patients need intermediate doses to manage side effects during titration.
Example: a patient tolerates 1 mg well but experiences severe nausea at 1.7 mg. The standard protocol is to stay at 1 mg longer, but some patients plateau at 1 mg and need a higher dose for continued weight loss. Compounded semaglutide allows a 1.3 mg or 1.5 mg dose, which may be tolerable.
This scenario is the original intent of compounding law: customization for individual medical need. It represents a small minority of compounded semaglutide use but is the most legally defensible.
When compounded semaglutide does NOT make sense:
- Insurance covers brand-name with reasonable copay (under $100/month)
- Patient is uncomfortable with self-injection or reconstitution
- Patient has high risk tolerance concerns and prefers FDA-approved products
- Patient is traveling internationally (compounded products may not clear customs)
Reconstitution and administration: what patients handle themselves
Brand-name semaglutide pens are ready to use. Compounded semaglutide requires patient preparation. This is the biggest practical barrier.
Standard reconstitution protocol:
- Receive shipment. Compounded semaglutide typically arrives as a vial of lyophilized (freeze-dried) powder, a vial of bacteriostatic water, alcohol wipes, and insulin syringes.
- Reconstitute. Add the specified volume of bacteriostatic water to the powder vial. Typical ratio is 2 mL water to 5 mg semaglutide powder, creating a 2.5 mg/mL concentration. Swirl gently (do not shake) until powder dissolves completely. This takes 1 to 3 minutes.
- Store. Place reconstituted vial in refrigerator (36-46°F). Discard after beyond-use date, typically 28 to 42 days.
- Draw dose. Using an insulin syringe, draw the prescribed volume. For example, if prescribed 0.5 mg and concentration is 2.5 mg/mL, draw 0.2 mL (20 units on a U-100 insulin syringe).
- Inject. Subcutaneous injection into abdomen, thigh, or upper arm. Rotate injection sites weekly.
- Dispose. Place used syringe in sharps container.
The process is similar to reconstituting other injectable medications like human growth hormone or certain fertility drugs. Patients who have used insulin or other injectables adapt quickly. Patients new to self-injection require more education.
Common reconstitution errors:
- Shaking instead of swirling. Vigorous shaking can denature the peptide. Gentle swirling is sufficient.
- Using tap water instead of bacteriostatic water. Tap water is not sterile and lacks preservatives. Reconstituted product would spoil within hours.
- Incorrect dose calculation. Concentration varies by pharmacy. Always verify mg/mL on the vial label and calculate volume accordingly.
- Reusing syringes. Insulin syringes are single-use. Reuse increases infection risk and causes needle dulling, which makes injections more painful.
Most telehealth platforms that prescribe compounded semaglutide provide video tutorials and written instructions. Some include a first-dose telehealth call where a nurse walks the patient through reconstitution in real time.
The reconstitution requirement is both a barrier and a filter. Patients willing to reconstitute tend to be more engaged and adherent. The extra step creates a commitment mechanism that may improve outcomes, though this hypothesis has not been tested in controlled trials.
The decision framework: should you use compounded semaglutide?
The choice between compounded and brand-name semaglutide depends on four variables: cost, availability, risk tolerance, and convenience preference. The framework below structures the decision.
Step 1: Check insurance coverage.
Call your insurance pharmacy benefits line. Ask:
- Is Wegovy covered for weight loss with prior authorization?
- Is Ozempic covered for weight loss off-label?
- What is the copay after prior authorization approval?
If copay is under $100/month and prior authorization is likely to be approved (BMI over 30, or over 27 with comorbidity), brand-name is usually the better choice. If coverage is denied or copay exceeds $300/month, move to step 2.
Step 2: Assess brand-name availability.
Check the FDA drug shortage database (accessdata.fda.gov/scripts/drugshortages). If semaglutide is listed as available, brand-name is an option. If listed as shortage, compounded is the only near-term option for most patients.
Step 3: Evaluate comfort with reconstitution.
Rate your comfort level with:
- Mixing medication from powder and liquid
- Drawing precise doses with a syringe
- Self-injecting weekly
- Storing medication properly
If you're uncomfortable with any of these, brand-name pens are more appropriate. If you're comfortable or willing to learn, compounded is viable.
Step 4: Weigh regulatory risk.
Compounded semaglutide has less oversight than FDA-approved products. The risk is not zero. Ask yourself:
- Do I trust the compounding pharmacy's quality control?
- Am I comfortable with a product that hasn't undergone FDA review?
- Do I have access to information about the pharmacy's accreditation and inspection history?
If regulatory assurance is a high priority, brand-name is the safer choice. If cost access is the higher priority, compounded is acceptable with eyes open to the tradeoff.
Step 5: Calculate total cost over 6 months.
Include medication cost, provider visits, supplies, and time cost of reconstitution. Compare:
- Brand-name with insurance: copay × 6 months
- Brand-name cash pay: $1,300 × 6 = $7,800
- Compounded via telehealth: $300 × 6 = $1,800
For most patients without insurance coverage, the cost difference is decisive.
FormBlends clinical pattern: Across our patient population, approximately 70% choose compounded semaglutide primarily for cost reasons, 20% choose it due to brand-name unavailability during shortage periods, and 10% choose it for dose customization. The patients who achieve the best outcomes are those who made an active choice after understanding the tradeoffs, rather than defaulting to compounded because it was the first option presented.
What happens when the shortage ends
The FDA has stated that once semaglutide is removed from the drug shortage list, compounding pharmacies must stop preparing semaglutide unless they can document patient-specific medical necessity for each prescription. This policy has created uncertainty for the estimated 2-3 million patients currently using compounded semaglutide.
Three possible scenarios:
Scenario 1: Immediate discontinuation.
The FDA removes semaglutide from the shortage list and enforces the prohibition on compounding. Compounding pharmacies stop dispensing semaglutide within 30 to 60 days. Patients must transition to brand-name products or discontinue treatment.
This scenario would create access problems for patients who cannot afford brand-name products and do not have insurance coverage. Some would transition to tirzepatide (Mounjaro/Zepbound), which may remain in shortage longer. Others would discontinue GLP-1 therapy entirely.
Scenario 2: Gradual transition with enforcement discretion.
The FDA removes semaglutide from the shortage list but allows a 6-12 month transition period for patients to switch to brand-name products or obtain prior authorization. Compounding pharmacies continue dispensing during the transition under enforcement discretion.
This scenario is more patient-friendly and mirrors the FDA's approach to other drug shortage resolutions. It would give patients time to navigate insurance approval and avoid treatment interruption.
Scenario 3: Continued compounding under medical necessity.
The FDA removes semaglutide from the shortage list, but compounding continues for patients who can document medical necessity. Prescribers write justifications for each prescription (for example, "patient requires 1.5 mg dose not available in commercial product" or "patient allergic to excipient in Wegovy formulation").
This scenario is legally permissible under 503A but would require prescribers to document necessity for each patient. The administrative burden would be significant, and enforcement would depend on FDA inspection priorities.
As of April 2026, the FDA has not announced which approach it will take. The agency's public statements emphasize that compounding is intended as a temporary solution during shortages, not a permanent alternative to FDA-approved products. Patient advocacy groups have lobbied for a gradual transition to avoid treatment disruption.
The most likely outcome is scenario 2: a transition period with enforcement discretion. This balances the FDA's regulatory mandate with practical patient access concerns.
FAQ
What is compound semaglutide? Compound semaglutide is the GLP-1 medication semaglutide prepared by a state-licensed compounding pharmacy instead of a pharmaceutical manufacturer. It contains the same active ingredient as Ozempic and Wegovy but is made to order for individual patients, typically at lower cost and without FDA approval.
Is compound semaglutide the same as Ozempic? The active ingredient is the same, but the formulation, delivery method, and regulatory status are different. Ozempic is FDA-approved and comes in a pre-filled pen. Compounded semaglutide is not FDA-approved and requires patient reconstitution from powder. They are not interchangeable products.
Is compound semaglutide safe? Compounded semaglutide prepared by a USP 797-compliant pharmacy has a safety profile comparable to brand-name products based on limited available data. The risk is higher than FDA-approved products due to less regulatory oversight, but serious adverse events are rare when prepared by accredited pharmacies.
How much does compound semaglutide cost? Typical cost is $200-$400 per month for a 4-week supply, compared to $900-$1,350 for brand-name products. Prices vary by pharmacy and whether the prescription is obtained through a telehealth platform or directly from a compounding pharmacy.
Is compound semaglutide legal? Yes, when prepared by a licensed 503A compounding pharmacy during an FDA drug shortage period or when a prescriber documents medical necessity for customization. It becomes legally questionable once the shortage ends unless patient-specific medical necessity is documented.
Do I need a prescription for compound semaglutide? Yes. Compounded semaglutide is a prescription medication. It can only be prepared after a licensed prescriber writes a patient-specific prescription. Online pharmacies offering semaglutide without a prescription are operating illegally.
Can I use my insurance for compound semaglutide? Rarely. Most insurance plans do not cover compounded medications. A few employers have added compounded GLP-1 coverage, but this represents less than 5% of the market. Patients typically pay cash.
How do I know if a compounding pharmacy is reputable? Look for PCAB accreditation, state pharmacy board licensure in good standing, and transparent communication about USP 797 compliance. Ask whether the pharmacy performs sterility and endotoxin testing. Avoid pharmacies making claims about "FDA-approved" or "generic" compounded semaglutide.
What is the difference between compound semaglutide and generic semaglutide? Generic semaglutide does not exist yet. Generics are FDA-approved copies of brand-name drugs, available only after patent expiration. Compounded semaglutide is not FDA-approved and is not a generic. The terms are not interchangeable.
How long does compound semaglutide last after reconstitution? Typical beyond-use date is 28 to 42 days when stored refrigerated at 36-46°F. The exact date depends on the pharmacy's formulation and stability testing. Always check the vial label and discard after the beyond-use date.
Can I travel with compound semaglutide? Domestic travel within the U.S. is fine if you keep the medication refrigerated. International travel is more complicated. Some countries do not allow entry of compounded medications, and customs may confiscate products without FDA approval. Check destination country regulations before traveling.
What happens if I miss a dose of compound semaglutide? If you miss a dose and it's been less than 5 days since your scheduled injection, take the missed dose as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Do not double dose.
Can I switch from Ozempic to compound semaglutide? Yes, but work with your prescriber to ensure dose continuity. The dosing increments may differ between brand-name and compounded versions. Your prescriber will calculate the equivalent dose based on the compounded product's concentration.
Does compound semaglutide work as well as Wegovy? The active ingredient is the same, so the pharmacological effect should be equivalent. No head-to-head trials have compared outcomes. Observational data from telehealth platforms suggests similar weight-loss results, but selection bias limits interpretation.
What should I do if I have side effects from compound semaglutide? Contact your prescriber. Common side effects (nausea, diarrhea, constipation) are usually manageable with dose adjustment or dietary changes. Severe side effects (persistent vomiting, severe abdominal pain, signs of pancreatitis) require immediate medical evaluation.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Aroda VR et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2017.
- Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide versus placebo. Diabetes Care. 2023.
- FDA Drug Shortage Database. Semaglutide injection shortage record. Accessed April 2026.
- United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2019.
- FDA. Compounding and the FDA: Questions and Answers. Updated 2024.
- Drug Quality and Security Act. Public Law 113-54. Section 503A. 2013.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- FDA Warning Letters to compounding pharmacies regarding semaglutide marketing. October 2023.
- Pharmacy Compounding Accreditation Board. Accreditation standards and directory. 2026.
- American College of Gastroenterology. GERD management guidelines. 2022.
- Novo Nordisk. Semaglutide supply update and manufacturing expansion announcement. December 2024.
- Obesity Week 2024. Retrospective safety analysis of compounded semaglutide in telehealth setting. Poster presentation.
- Medicare Modernization Act of 2003. Section 1860D-2(e)(2)(A). Weight-loss medication exclusion.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.